China Begin Period Cash Flow from 2010 to 2024
| CPHI Stock | USD 0.20 0.01 5.26% |
Begin Period Cash Flow | First Reported 2001-09-30 | Previous Quarter 838.9 K | Current Value 739.3 K | Quarterly Volatility 2.1 M |
Check China Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among China Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.9 M, Interest Expense of 350.4 K or Selling General Administrative of 1.4 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0019 or PTB Ratio of 0.29. China financial statements analysis is a perfect complement when working with China Pharma Valuation or Volatility modules.
China | Begin Period Cash Flow |
Latest China Pharma's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of China Pharma Holdings over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. China Pharma's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in China Pharma's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
China Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 3,222,314 | |
| Geometric Mean | 2,090,732 | |
| Coefficient Of Variation | 57.97 | |
| Mean Deviation | 1,548,427 | |
| Median | 2,823,581 | |
| Standard Deviation | 1,867,916 | |
| Sample Variance | 3.5T | |
| Range | 6.2M | |
| R-Value | (0.20) | |
| Mean Square Error | 3.6T | |
| R-Squared | 0.04 | |
| Significance | 0.49 | |
| Slope | (81,633) | |
| Total Sum of Squares | 48.8T |
China Begin Period Cash Flow History
About China Pharma Financial Statements
Investors use fundamental indicators, such as China Pharma's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although China Pharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 2 M | 2.8 M |
Currently Active Assets on Macroaxis
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:Check out the analysis of China Pharma Correlation against competitors. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.63 | Quarterly Revenue Growth (0.16) | Return On Assets (0.18) | Return On Equity (0.75) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.